Literature DB >> 7625570

Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase.

D Lucas1, C Ménez, C Girre, P Bodénez, E Hispard, J F Ménez.   

Abstract

To evaluate cytochrome P4502E1 (CYP2E1) induction in alcoholics, the ratio of the concentrations of 6-hydroxychlorzoxazone (6-OH-CHZ) and chlorzoxazone (CHZ) was measured in blood 2 hr after CHZ ingestion using a HPLC method. This ratio was determined in controls and in alcoholic patients after 1, 2, 3, 4, 5, 8, and 21 days withdrawal. It was found to be 0.34 +/- 0.03 in 30 controls and 1.05 +/- 0.14 in 41 alcoholic patients within 2 days following ethanol withdrawal. This ratio decreased rapidly during withdrawal as attested by the short half-life of CYP2E1, which was found to be 2.5 days. Patients tested for CHZ metabolism after 8 or 21 days alcohol abstinence displayed the same ratio as controls [0.35 +/- 0.03 (n = 28) and 0.31 +/- 0.03 (n = 34), respectively]. No correlation was observed between gamma-glutamyltransferase, carbohydrate-deficient transferrin values, the amount of alcohol consumed/day, and the 6-OH-CHZ/CHZ ratio. There was no influence of smoking on the rate of CHZ hydroxylation, because smokers displayed the same ratio as nonsmokers [0.33 +/- 0.025 (n = 62) and 0.33 +/- 0.02 (n = 30), respectively]. The CHZ hydroxylation ratio seems to be a good reflection of the hepatic and extrahepatic CYP2E1 activity in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625570     DOI: 10.1111/j.1530-0277.1995.tb01516.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  11 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans.

Authors:  Iza Kramer; Kim Dalhoff; Jens O Clemmesen; Steffen Loft; Henrik E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  2003-11-11       Impact factor: 2.953

3.  Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.

Authors:  Jie Wan; Lena Ernstgård; Byoung J Song; Susan E Shoaf
Journal:  J Pharm Pharmacol       Date:  2006-01       Impact factor: 3.765

4.  Ultra-rapid rate of ethanol elimination from blood in drunken drivers with extremely high blood-alcohol concentrations.

Authors:  Alan Wayne Jones
Journal:  Int J Legal Med       Date:  2007-06-16       Impact factor: 2.686

5.  Obesity-induced CYP2E1 activity in children.

Authors:  Christina Gade; Kim Dalhoff; Tonny Petersen; Troels Riis; Camilla Schmeltz; Elizaveta Chabanova; Hanne Rolighed Christensen; Gerd Mikus; Juergen Burhenne; Jens Christian Holm; Helle Holst
Journal:  Br J Clin Pharmacol       Date:  2018-12-09       Impact factor: 4.335

6.  Patterns of acetaminophen use exceeding 4 grams daily in a hospitalized population at a tertiary care center.

Authors:  Jesse M Civan; Victor Navarro; Steven K Herrine; Jeffrey M Riggio; Paul Adams; Simona Rossi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-01

Review 7.  Paracetamol, alcohol and the liver.

Authors:  L F Prescott
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

8.  Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism?: a case against.

Authors:  Paul I Dargan; Alison L Jones
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  The predicted impact of reducing the nicotine content in cigarettes on alcohol use.

Authors:  Sarah S Dermody; Eric C Donny
Journal:  Nicotine Tob Res       Date:  2014-03-19       Impact factor: 4.244

10.  The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study.

Authors:  E K Kuffner; J L Green; G M Bogdan; P C Knox; R B Palmer; K Heard; J T Slattery; R C Dart
Journal:  BMC Med       Date:  2007-05-30       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.